共 10 条
[1]
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind; randomised phase 3 trial[J] Hansjochen Wilke;Kei Muro;Eric Van Cutsem;Sang-Cheul Oh;György Bodoky;Yasuhiro Shimada;Shuichi Hironaka;Naotoshi Sugimoto;Oleg Lipatov;Tae-You Kim;David Cunningham;Philippe Rougier;Yoshito Komatsu;Jaffer Ajani;Michael Emig;Roberto Carlesi;David Ferry;Kumari Chandrawansa;Jonathan D Schwa
[2]
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international; randomised; multicentre; placebo-controlled; phase 3 trial[J] Charles S Fuchs;Jiri Tomasek;Cho Jae Yong;Filip Dumitru;Rodolfo Passalacqua;Chanchal Goswami;Howard Safran;Lucas Vieira dos Santos;Giuseppe Aprile;David R Ferry;Bohuslav Melichar;Mustapha Tehfe;Eldar Topuzov;John Raymond Zalcberg;Ian Chau;William Campbell;Choondal Sivanandan;Joanna Pikiel;Minori Kos
[3]
Effectiveness and safety profile of S?1?based chemotherapy comparedwith capecitabine?based chemotherapy for advanced gastric and colorectal cancer:A meta?analysis[J] Jia-Xiang Ye;Ai-Qun Liu;Lian-Ying Ge;Shao-Zhang Zhou;Zhong?Guo Liang Experimental and Therapeutic Medicine 2014,
[4]
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study[J] J.A. Ajani;M. Buyse;M. Lichinitser;V. Gorbunova;G. Bodoky;J.Y. Douillard;S. Cascinu;V. Heinemann;R. Zaucha;A. Carrato;D. Ferry;V. Moiseyenko European Journal of Cancer 2013,
[5]
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)[J] Peter C. Thuss-Patience;Albrecht Kretzschmar;Dmitry Bichev;Tillman Deist;Axel Hinke;Kirstin Breithaupt;Yasemin Dogan;Bernhard Gebauer;Guido Schumacher;Peter Reichardt European Journal of Cancer 2011,
[6]
Effectiveness and safety of oxaliplatin compared to cisplatin for advanced; unresectable gastric cancer: a systematic review and meta-analysis[J] Francesco Montagnani;Gina Turrisi;Claudio Marinozzi;Camillo Aliberti;Giammaria Fiorentini Gastric Cancer 2011,
[7]
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3; open-label; randomised controlled trial[J] Yung-Jue Bang;Eric Van Cutsem;Andrea Feyereislova;Hyun C Chung;Lin Shen;Akira Sawaki;Florian Lordick;Atsushi Ohtsu;Yasushi Omuro;Taroh Satoh;Giuseppe Aprile;Evgeny Kulikov;Julie Hill;Michaela Lehle;Josef Rüschoff;Yoon-Koo Kang The Lancet 2010,
[8]
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study[J] Narikazu Boku;Seiichiro Yamamoto;Haruhiko Fukuda;Kuniaki Shirao;Toshihiko Doi;Akira Sawaki;Wasaburo Koizumi;Hiroshi Saito;Kensei Yamaguchi;Hiroya Takiuchi;Junichiro Nasu;Atsushi Ohtsu Lancet Oncology 2009,
[9]
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial[J] Wasaburo Koizumi;Hiroyuki Narahara;Takuo Hara;Akinori Takagane;Toshikazu Akiya;Masakazu Takagi;Kosei Miyashita;Takashi Nishizaki;Osamu Kobayashi;Wataru Takiyama;Yasushi Toh;Takashi Nagaie;Seiichi Takagi;Yoshitaka Yamamura;Kimihiko Yanaoka;Hiroyuki Orita;Masahiro Takeuchi Lancet Oncology 2008,
[10]
Phase II Study of Biweekly Paclitaxel Plus Infusional 5-Fluorouracil and Leucovorin as First-Line Chemotherapy in Patients With Advanced Gastric Cancer Fenghua Wang;Zhiqiang Wang;Ningning Zhou; AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 2011,